Jacalyn M. Rosenblatt
Expertise in
17
conditions

Dr. Jacalyn M. Rosenblatt

Internal Medicine
330 Brookline Avenue, 
Boston, MA 
Accepting New Patients
Before you request
Expertise in
17
conditions
330 Brookline Avenue, 
Boston, MA 

Overview

Jacalyn Rosenblatt is a primary care provider, practicing in Internal Medicine in Boston, Massachusetts.

Dr. Rosenblatt is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Smoldering Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Dr. Rosenblatt is board certified in American Board Of Internal Medicine and Royal College Of Physicians And Surgeons Of Canada. She is actively involved in clinical research, co-authoring 79 peer reviewed articles and participating in 12 clinical trials. Dr. Rosenblatt is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in MA

Board Certifications

American Board Of Internal Medicine
Royal College Of Physicians And Surgeons Of Canada

Fellowships

McGill University Faculty of Medicine
Beth Israel Deaconess Medical Center

Hospital Affiliations

Beth Israel Deaconess Hospital - Needham
Beth Israel Deaconess Medical Center

Languages Spoken

English
French

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Boston, MA 02215

Additional Areas of Focus

Dr. Rosenblatt has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Multiple Myeloma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Drug
Study Drugs: Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone
Study Phase: Phase 2
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2026
Intervention Type: Drug
Study Drugs: Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase I/II Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
A Phase I/II Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
Enrollment Status: Completed
Publish Date: May 29, 2026
Intervention Type: Drug
Study Drug: Abatacept
Study Phase: Phase 1/Phase 2
A Phase I Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Alone and in Conjunction With Decitabine Following Allogeneic Transplantation in AML Patients
A Phase I Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Alone and in Conjunction With Decitabine Following Allogeneic Transplantation in AML Patients
Enrollment Status: Active_not_recruiting
Publish Date: May 12, 2026
Intervention Type: Biological
Study Drugs: Decitabine, DC/AML fusion cells
Study Phase: Phase 1
A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drug: Daratumumab
Study Phase: Phase 2
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drug: CART-ddBCMA
Study Phase: Phase 1
A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission
A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Other, Biological
Study Drug: Dendritic Cell Fusion Vaccine
Study Phase: Phase 2
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: AO-176, AO-176 + Dex, AO-176 + Dex + Bort
Study Phase: Phase 1/Phase 2
A Phase II Trial of Vaccination With Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
A Phase II Trial of Vaccination With Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
Enrollment Status: Terminated
Publish Date: June 22, 2023
Intervention Type: Biological, Drug
Study Drugs: Nivolumab, DC/Myeloma Fusions/GM-CSF
Study Phase: Phase 2
A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: July 18, 2022
Intervention Type: Procedure, Biological, Drug
Study Drugs: Busulfan, Fludarabine, Tacrolimus, Methotrexate, GM-CSF-Positive GVAX Vaccine
Study Phase: Phase 2
View 9 Less Clinical Trials

79 Total Publications

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.
Journal: Nature communications
Published: August 01, 2025
Similar Doctors
Expertise in
24
conditions
Dr. Nezam H. Afdhal
Internal Medicine
Expertise in
24
conditions
Dr. Nezam H. Afdhal
Internal Medicine
Before you request

BIDMC - Division Of Gastroenterology/Liver Center

110 Francis Street, 
Boston, MA 
 (0.3 miles away)
617-632-1070
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Nezam Afdhal is a primary care provider, practicing in Internal Medicine in Boston, Massachusetts. Dr. Afdhal is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Endoscopy. Dr. Afdhal is currently accepting new patients.

Expertise in
22
conditions
Dr. Gabriela S. Hobbs
Internal Medicine
Expertise in
22
conditions
Dr. Gabriela S. Hobbs
Internal Medicine

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-724-1124
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gabriela Hobbs is a primary care provider, practicing in Internal Medicine in Boston, Massachusetts. She has been practicing medicine for over 18 years. Dr. Hobbs is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Myelofibrosis, Polycythemia Vera, Bone Marrow Aspiration, and Colonoscopy. Dr. Hobbs is currently accepting new patients.

Expertise in
24
conditions
Dr. Adnan J. Majid
Internal Medicine
Expertise in
24
conditions
Dr. Adnan J. Majid
Internal Medicine
Before you request

Medical And Surgical Specialties

200 Boylston Street, 
Chestnut Hill, MA 
 (3.9 miles away)
617-632-8252
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Adnan Majid is a primary care provider, practicing in Internal Medicine in Chestnut Hill, Massachusetts. Dr. Majid is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Tracheobronchomalacia, Acquired Tracheomalacia, Parapneumonic Pleural Effusion, Advanced Bronchoscopy, and Endoscopy. Dr. Majid is board certified in American Board Of Internal Medicine. Dr. Majid is currently accepting new patients.

Frequently Asked Questions about Dr. Jacalyn M. Rosenblatt

How do I make an appointment with Dr. Jacalyn M. Rosenblatt?

You can book an appointment with Dr. Jacalyn M. Rosenblatt by calling their office at 617-667-9920. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jacalyn M. Rosenblatt a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jacalyn M. Rosenblatt is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jacalyn M. Rosenblatt specialize in?

While Dr. Jacalyn M. Rosenblatt is a Internal Medicine, they have specific expertise in Multiple Myeloma, Acute Myeloid Leukemia (AML), and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Jacalyn M. Rosenblatt participate in research or clinical trials?

Yes. Dr. Jacalyn M. Rosenblatt has published 79 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Jacalyn M. Rosenblatt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jacalyn M. Rosenblatt accept my insurance?

Dr. Jacalyn M. Rosenblatt accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-667-9920 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosenblatt's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile